Disclosure of pharmacokinetic drug results to understand nonadherence

AIDS

Volumn 29, Issue 16, 2015, Pages 2161-2171

  Van Der Straten, Ariane ^a,b   Montgomery, Elizabeth T ^a   Musara, Petina ^c   Etima, Juliane ^d   Naidoo, Sarita ^e   Laborde, Nicole ^a   Hartmann, Miriam ^a   Levy, Lisa ^f   Bennie, Thola ^g   Cheng, Helen ^a   Piper, Jeanna ^h   Grossman, Cynthia I ⁱ   Marrazzo, Jeanne ^j   Mensch, Barbara ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d MAKERERE UNIVERSITY   (Uganda)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^f FHI 360   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k POPULATION COUNCIL   (United States)

more..

Author keywords

adherence; HIV preexposure prophylaxis; microbicide; pharmacokinetic drug detection; VOICE D Study; women

Indexed keywords

TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DRUG MONITORING; DRUG WITHDRAWAL; EMOTION; FEEDBACK SYSTEM; FEMALE; FOCUS GROUP DISCUSSION; GROUP DYNAMICS; HAPPINESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN DEPTH INTERVIEW; INFECTION PREVENTION; INTERPERSONAL COMMUNICATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOTIVATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; SIDE EFFECT; SOUTH AFRICA; SURPRISE; TREATMENT REFUSAL; UGANDA; WAITING ROOM; ZIMBABWE; CHEMISTRY; HIV INFECTIONS; PLASMA; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; PLASMA; RETROSPECTIVE STUDIES; SOUTH AFRICA; TENOFOVIR; UGANDA; YOUNG ADULT; ZIMBABWE;

EID: 84964877842     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000801     Document Type: Article

References (45)

1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic: 2013. Geneva: UNAIDS; 2013.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
3. Rees H, Delany-Morelwe SA, Lombard C. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Conference on Retroviruses and Opportunistic Infections (CROI); 23-26 February 2015, Seattle, WA. pp. 23-26.
4. Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep 2013; 10:1-10.
5. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
6. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet 2013; 381:2083-2090.
7. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
8. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
9. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of preexposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-F19.
10. Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral preexposure prophylaxis. Annu Rev Med 2013; 64:219-232.
11. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
12. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509-518.
13. Buchbinder S, Liu A. CROI 2015: advances in HIV testing and prevention strategies. Top Antivir Med 2015; 23:8-27.
14. van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep 2013; 10:89-102.
15. Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav 2010; 14:1124-1136.
16. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013; 8:e55013.
17. Hendrix CW, Andrade A, Kashuba A, Marzinke M, Anderson PL, Moore A, et al. Tenofovir-emtricitabine directly observed dosing: 100% adherence concentrations (HPTN 066). 21st Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA.
18. Hendrix CW. Exploring concentration response in HIV preexposure prophylaxis to optimize clinical care and trial design. Cell 2013; 155:515-518.
19. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of preexposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14:820-829.
20. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.
21. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C Qualitative Study in Johannesburg, South Africa. PLoS One 2014; 9:e89118.
22. Magazi B, Stadler J, Delany-Moretlwe S, Montgomery E, Mathebula F, Hartmann M, et al. Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa. BMC Womens Health 2014; 14:88.
23. Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, et al. Male partner influence on women's HIV prevention trial participation and use of preexposure prophylaxis: the importance of 'understanding'. AIDS Behav 2015; 19:784-793.
24. van der Straten A, Mensch B, Montgomery ET. MTN-003D: an exploratory study of potential sources of efficacy dilution in the VOICE trial. Kampala, Uganda, Durban, South Africa and Chitungwiza, Zimbabwe: DAIDS; 2013.
25. Naidoo S, Woeber K, Munaiwa O, Etima J, Duby Z, Hartmann M, et al. Application of a body map tool to enhance discussion of sexual behaviour in women: experiences from MTN 003D. AIDS Res Hum Retrov 2014; 30:A11-A111.
26. Duby Z, Hartmann M, Mahaka I, Montgomery ET, Colvin CJ, Mensch B, et al. Language, terminology and understanding of anal sex amongst VOICE participants in Uganda, Zimbabwe and South Africa. AIDS Res Hum Retrov 2014; 30:A10-A11.
27. Duby Z, Hartmann M, Montgomery ET, Colvin CJ, Mensch B, van der Straten A. Perceptions and practice of heterosexual anal sex amongst VOICE participants in Uganda, Zimbabwe and South Africa. AIDS Res Hum Retrov 2014; 30:A269-A269.
28. van der Straten A, Montgomery E, Hartmann M, Levy L, Piper J, Mensch B. Strategies to explore factors impacting study product adherence among women in VOICE. IAPAC Conference; 2014 June 8-10; Miami, FL.
29. Eckman P. Basic emotions. In: Dalgleish T, Power M, editors. Handbook of cognition and emotion Sussex, UK: John Wiley & Sons Ltd; 1999.
30. Guest G, MacQueen KM. Handbook for team-based qualitative research. Altamira: Rowman; 2007.
31. Etima J, Nakabiito C, Akello CA, Kabwigu S, Nakyanzi T, Nabukeera J, et al. To give or not to give PK results: an ethical dilemma for researchers & regulators in Uganda. AIDS Res Hum Retrov 2014; 30:A42-A142.
32. Musara P, Munaiwa O, Mahaka I, Mgodi NM, Hartmann M, Levy L, et al. The effect of presentation of pharmacokinetic (PK) drug results on self-reported study product adherence among VOICE participants in Zimbabwe. AIDS Res Hum Retrov 2014; 30:A42-A142.
33. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
34. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol 2012; 52:275-301.
35. van der straten A, Stadler J, Luecke E, Laborde N, Hartmann MEM. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc 2014; 17:19146.
36. Bekker L-G, Grant R, Hughes J, Roux S, Amico R, Hendrix C, et al. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. Conference on Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, WA.
37. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013; 10:e1001511.
38. Microbicide Trials Network (MTN). Researchers launch firstever Phase II safety study of a rectal microbicide to prevent HIV. Pittsburgh, PA: Microbicide Trials Network; 2013.
39. Microbicide Trials Network (MTN). Questions and Answers: VOICE C and VOICE D social and behavioral research substudies of VOICE. Rossi L. editor. Pittsburgh, PA: Microbicide Trials Network; 2014. See http://www.mtnstopshiv.org/news/ studies/mtn003cd/qa
40. Mensch BS, van der Straten A, Hartmann M, Cheng H, Miller B, Piper J, et al. Reporting of challenges to adherence in VOICE: a comparison of quantitative and qualitative self-reports among women during and after the trial. AIDS Res Hum Retrov 2014; 30:A252-A1252.
41. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. White Coat Compliance' limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008; 9:238-246.
42. Corneli AL, McKenna K, Perry B, Ahmed K, Micro M, Agot K, et al. The science of being a study participant: FEM-PrEP participants' explanations for over-reporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr 2015; 68:578-584.
43. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013; 17:2143-2155.
44. van der Straten A, Mayo A, Brown E, Amico KR, Cheng H, Laborde N, et al. Perceptions and experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS Behav 2015; 19:770-783.
45. Schwartz K, Ndase P, Torjesen K, Mayo A, Scheckter R, van der Straten A, et al. Supporting participant adherence through structured engagement activities in the MTN-020 (aspire) trial. AIDS Res Hum Retrov 2014; 30:A80-A180.